- Aug 14, 2013
- 2,455
- Tinnitus Since
- Resolved since 2016
- Cause of Tinnitus
- Unknown (medication, head injury)
We have to assume that the data review was done very thoroughly by highly competent scientists.I hope that they will find some kind of subgroup in their data that actually were helped by the drug but I am also a bit surprised that they could draw these kind of conclusions based on 58 people, which is only about one third of what they planed on. Would another 100 have changed the outcome? Is it possible that they are on the right track regarding what to target but their drug just didn't work well enough?
But... reality influences science regardless of intelligence, and, if the patient intake had been more massive early on, then I, too, cannot help but play the mind game of "would that have changed anything"?
58 patients is indeed not much, and, with a heterogeneous condition such as tinnitus, even for a standardized patient population, then perhaps a larger sample would have changed the outcome (the AM-101 phase-II trial also only detected efficacy in a small sub-group of patients). But we have to remember the involvement of the GAP detection model used in pre-clinical studies, and, it is possible that the signs of tinnitus reduction (from those studies) in fact were "something" else (than what was being measured).
We have to trust that the investigators of Autifony know what they are doing, regardless of my above speculation.